Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257083 · ClinicalTrials.gov registry record · Phase 3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Stichting European Myeloma Network.
- Active
- Registry status
- Phase 3
- Development phase
- 759
- Enrollment target
- 20
- Study locations
NCT05257083: Active Phase 3 study of Multiple Myeloma, sponsored by Stichting European Myeloma Network.
NCT05257083 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Stichting European Myeloma Network. The registered enrollment target is 759 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05257083, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Stichting European Myeloma Network.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 759 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Cilta-cel
- DRUG Bortezomib
Study Locations (20)
California
- City of Hope - Duarte
- UC San Diego Health Moores Cancer Center - San Diego
- University of California San Francisco (UCSF) - San Francisco
- Stanford University - Stanford
New York
- Mount Sinai Medical Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
- University of Rochester - Rochester
- Montefiore M-E Center - The Bronx
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- Levine Cancer Institute - Charlotte
- Duke University Medical Center - Durham
Arkansas
- University of Arkansas - Little Rock
Florida
- Moffit Cancer Center - Tampa
Georgia
- Emory University Hospital - Atlanta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 759 participants |
| Start Date | 2023-10-10 |
| Est. Completion | 2040-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05257083
The ClinicalTrials.gov registry entry for NCT05257083 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 759 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (39% higher). The listed sponsor is Stichting European Myeloma Network, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT05257083 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05257083 about?
NCT05257083 is a clinical study titled "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed mul...
What is the current status of trial NCT05257083?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 759 participants. The study started on 2023-10-10. Estimated completion is 2040-08.
What conditions does trial NCT05257083 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05257083?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Cilta-cel (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT05257083?
This trial is sponsored by Stichting European Myeloma Network, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05257083 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.